Hot Features
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company’s lead drug candidate is the BIO101 to treat obesity, respiratory infections due... Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company’s lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. It also has an alliance with LynxKite Technologies Pte Ltd for the development of AI-driven drug discovery for longevity therapies. The company was incorporated in 2006 and is headquartered in Paris, France. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 12 | -0.2 | -44.4444444444 | 0.45 | 0.45 | 0.25 | 888 | 0.25386492 | DR |
| 26 | -0.662 | -72.5877192982 | 0.912 | 0.912 | 0.001 | 629 | 0.20708795 | DR |
| 52 | -1.13 | -81.884057971 | 1.38 | 2 | 0.001 | 406 | 0.57827094 | DR |
| 156 | -7.8 | -96.8944099379 | 8.05 | 10.25 | 0.001 | 787 | 4.48541884 | DR |
| 260 | -7.8 | -96.8944099379 | 8.05 | 10.25 | 0.001 | 787 | 4.48541884 | DR |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.